S Behboudi-Gandevani1, F Ramezani Tehrani2, R Bidhendi Yarandi3, M Noroozzadeh1, M Hedayati4, F Azizi5. 1. Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, No 24, Parvane Street, Yaman Street, Velenjak, P.O. Box: 19395-4763, Tehran, Iran. 2. Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, No 24, Parvane Street, Yaman Street, Velenjak, P.O. Box: 19395-4763, Tehran, Iran. ramezani@endocrine.ac.ir. 3. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 4. Cellular & Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
PURPOSE: This study aimed to investigate the interactive effect of polycystic ovary syndrome (PCOS) status and obesity status on the serum levels of adipokines. METHODS: In this comparative case-control cross-sectional study, 58 women with PCOS and 104 eumenorrheic non-hirsute women as the control group were recruited. They were further divided into two subgroups of overweight/obese and normal weight. The interactive effect of the PCOS status and obesity status on the circulating levels of adipokines was assessed using general linear model with the adjustment of age. RESULTS: A statistically significant negative interaction was reported between obesity status and PCOS status in the determination of serum adiponectin and resistin concentrations (effect size = -0.14, interaction P = 0.001, effect size = -0.15, P = 0.016). It indicated that adiponectin and resistin were significantly decreased in overweight/obese patients with PCOS compared with other subgroups. Statistically significant positive interactive effects were found between PCOS status obesity status and leptin (effect size = 0.321, interaction P = 0.036), indicating that the overweight/obese women with PCOS had the higher levels of leptin compared with the control group. Also, no interaction was reported between PCOS status and obesity status with regard to the serum levels of other adipokines. CONCLUSIONS: While no sufficient evidence is available with regard to the causal association between adipokines and PCOS, they may contribute to the development of PCOS and regarded as the novel biomarkers of PCOS.
PURPOSE: This study aimed to investigate the interactive effect of polycystic ovary syndrome (PCOS) status and obesity status on the serum levels of adipokines. METHODS: In this comparative case-control cross-sectional study, 58 women with PCOS and 104 eumenorrheic non-hirsute women as the control group were recruited. They were further divided into two subgroups of overweight/obese and normal weight. The interactive effect of the PCOS status and obesity status on the circulating levels of adipokines was assessed using general linear model with the adjustment of age. RESULTS: A statistically significant negative interaction was reported between obesity status and PCOS status in the determination of serum adiponectin and resistin concentrations (effect size = -0.14, interaction P = 0.001, effect size = -0.15, P = 0.016). It indicated that adiponectin and resistin were significantly decreased in overweight/obesepatients with PCOS compared with other subgroups. Statistically significant positive interactive effects were found between PCOS status obesity status and leptin (effect size = 0.321, interaction P = 0.036), indicating that the overweight/obesewomen with PCOS had the higher levels of leptin compared with the control group. Also, no interaction was reported between PCOS status and obesity status with regard to the serum levels of other adipokines. CONCLUSIONS: While no sufficient evidence is available with regard to the causal association between adipokines and PCOS, they may contribute to the development of PCOS and regarded as the novel biomarkers of PCOS.
Authors: H C Mendonça; R M Montenegro; R M Montenegro; M C Foss; M F Silva de Sá; R A Ferriani Journal: Braz J Med Biol Res Date: 2004-04-22 Impact factor: 2.590
Authors: D Romualdi; V Versace; V Tagliaferri; S De Cicco; V Immediata; R Apa; M Guido; A Lanzone Journal: J Endocrinol Invest Date: 2019-03-07 Impact factor: 4.256
Authors: Maha H Daghestani; Mazin Daghestani; Mamoon Daghistani; Akmal El-Mazny; Geir Bjørklund; Salvatore Chirumbolo; Samar H Al Saggaf; Arjumand Warsy Journal: Lipids Health Dis Date: 2018-08-21 Impact factor: 3.876
Authors: Maha H Daghestani; Mazin H Daghestani; Mamoon H Daghistani; Geir Bjørklund; Salvatore Chirumbolo; Arjumand Warsy Journal: BMC Womens Health Date: 2019-01-11 Impact factor: 2.809